Literature DB >> 15343606

Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature.

J M P J Breur1, G H A Visser, A A Kruize, P Stoutenbeek, E J Meijboom.   

Abstract

The presence of maternal autoantibodies to SS-A/Ro and/or SS-B/La is associated with the development of fetal heart block. There are data suggesting that maternal treatment with steroids might reverse heart block. We report on a pregnancy in a mother with secondary Sjögren syndrome and systemic lupus erythematosus with presence of autoantibodies to SS-A/Ro and SS-B/La, which was complicated by the development of incomplete fetal heart block. Oral dexamethasone treatment could not prevent progression to complete heart block and was associated with a number of complications.A review of the literature revealed 19 studies (including ours) in which 93 cases of fetal heart block were treated with maternal steroid therapy. Complete heart block proved irreversible in all cases; and of 13 fetuses with incomplete heart block which received maternal steroid therapy, three had a reduction in their degree of block and one reverted to sinus rhythm. Maternal steroid therapy, initiated early in pregnancy and potentially preventing the onset of heart block, did not decrease the incidence of heart block in nine studies with 43 cases. Furthermore, the literature review revealed numerous serious side effects of maternal steroid administration during pregnancy. Data on these potential side effects are lacking in the 28 studies discussed in this review. Maternal dexamethasone therapy to prevent or treat fetal heart block remains, in our opinion, a questionable intervention and can as yet not be recommended in the clinical situation. Copyright 2004 ISUOG

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15343606     DOI: 10.1002/uog.1713

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  18 in total

Review 1.  Prenatal pharmacotherapy for fetal anomalies: a 2011 update.

Authors:  Lisa Hui; Diana W Bianchi
Journal:  Prenat Diagn       Date:  2011-06-03       Impact factor: 3.050

Review 2.  Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus.

Authors:  Peter Izmirly; Amit Saxena; Jill P Buyon
Journal:  Curr Opin Rheumatol       Date:  2017-09       Impact factor: 5.006

3.  Cardiac fibroblast transcriptome analyses support a role for interferogenic, profibrotic, and inflammatory genes in anti-SSA/Ro-associated congenital heart block.

Authors:  Robert M Clancy; Androo J Markham; Tanisha Jackson; Sara E Rasmussen; Miroslav Blumenberg; Jill P Buyon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

Review 4.  Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.

Authors:  Antonio Brucato; Rolando Cimaz; Roberto Caporali; Véronique Ramoni; Jill Buyon
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

Review 5.  Management of pregnancy in systemic lupus erythematosus.

Authors:  Aisha Lateef; Michelle Petri
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

Review 6.  Inflammatory bowel diseases and human reproduction: a comprehensive evidence-based review.

Authors:  Stefano Palomba; Giuliana Sereni; Angela Falbo; Marina Beltrami; Silvia Lombardini; Maria Chiara Boni; Giovanni Fornaciari; Romano Sassatelli; Giovanni Battista La Sala
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 7.  Managing lupus patients during pregnancy.

Authors:  Aisha Lateef; Michelle Petri
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-06       Impact factor: 4.098

Review 8.  Perinatal arrhythmias: diagnosis and management.

Authors:  Janette F Strasburger; Bageshree Cheulkar; Heather J Wichman
Journal:  Clin Perinatol       Date:  2007-12       Impact factor: 3.430

9.  Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study.

Authors:  Deborah M Friedman; Mimi Y Kim; Joshua A Copel; Carolina Llanos; Claudine Davis; Jill P Buyon
Journal:  Am J Cardiol       Date:  2009-03-04       Impact factor: 2.778

10.  Atrioventricular block: a serious complication in and after transcatheter closure of perimembranous ventricular septal defects.

Authors:  Tao Zhou; Xiang-Qian Shen; Sheng-Hua Zhou; Zhen-Fei Fang; Xin-Qun Hu; Yan-Shu Zhao; Shu-Shan Qi; Zheng Zhou; Jiang Li; Xiao-Lin Lv
Journal:  Clin Cardiol       Date:  2008-08       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.